Cologuard is included in major screening guidelines and quality measures, making it part of the standard of care for colorectal cancer screening.
Healthcare Effectiveness Data and Information Set (HEDIS)®*8
The National Committee for Quality Assurance (NCQA) includes Cologuard within its HEDIS®* quality measures with 3 years of credit8
*Percentage reporting that Cologuard “met or exceeded expectations”
*Stool DNA (i.e. Cologuard) is one of the methods permitted as part of NCQA’s HEDIS® quality measures for colon cancer screening. Third party guidelines and quality measures do not specifically “endorse” commercial products, and inclusion in same does not imply otherwise.
REFERENCES 1. Bibbins-Domingo K, Grossman DC, Curry SJ, et al; for US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2016;315(23):2564-2575. 2. American Cancer Society. American Cancer Society guidelines for early detection of cancer. American Cancer Society website. Revised October 20, 2015. Accessed January 20, 2016. 3. National Comprehensive Cancer Network®. NCCN Guidelines®. Colorectal cancer screening. Version 2.2016. National Comprehensive Cancer Network website. Accessed February 9, 2017. 4. Decision Memo for Screening for Colorectal Cancer - Stool DNA Testing (CAG-00440N). Centers for Medicare & Medicaid Services website. Accessed August 15, 2018. 5. Announcement of Calendar Year (CY) 2018 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter and Request for Information. Updated April 3, 2017. Accessed August 14, 2018. 6. eCQMS. Accessed August 15, 2018. 7. Uniform Data System (UDS) Resources. Accessed August 15, 2018. 8. National Committee for Quality Assurance website. HEDIS 2017 Volume 2 Technical Update. Accessed August 14, 2018. 9. Internal data. Exact Sciences Laboratories. Cologuard Ordering Physician Research; as of June 30, 2018.